Category NEWS

Immunomic Therapeutics

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001

HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001 Immunomic Therapeutics Inc., a clinical-stage biotechnology company and a subsidiary of HLB, announced that the first participant has been dosed in the Phase…

Read MoreImmunomic Therapeutics Doses First Patient in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001
Brenus

Brenus Pharma Strengthens Governance with New President and Independent Board Appointment

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member Brenus Pharma announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE as President & Chairman of…

Read MoreBrenus Pharma Strengthens Governance with New President and Independent Board Appointment
Arima Genomics

Arima Genomics Partners with Active Motif to Expand Distribution of Research Hi-C Sequencing Kits and Services

Arima Genomics Announces Distribution Partnership with Active Motif for Research-Specific Hi-C Sequencing Kits and Services   Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced a distribution partnership with…

Read MoreArima Genomics Partners with Active Motif to Expand Distribution of Research Hi-C Sequencing Kits and Services
Celea Therapeutics

Celea Therapeutics Secures $180 Million to Advance Deupirfenidone for Idiopathic Pulmonary Fibrosis Treatment

Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) Celea Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with serious respiratory diseases, today…

Read MoreCelea Therapeutics Secures $180 Million to Advance Deupirfenidone for Idiopathic Pulmonary Fibrosis Treatment
PureTech

PureTech-Founded Celea Therapeutics Raises $180 Million to Accelerate Deupirfenidone Development for IPF

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation…

Read MorePureTech-Founded Celea Therapeutics Raises $180 Million to Accelerate Deupirfenidone Development for IPF
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program

AGC Pharma Chemicals Validates CDMO Facilities Through Scientist.com’s VERIF.i® Program

AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule…

Read MoreAGC Pharma Chemicals Validates CDMO Facilities Through Scientist.com’s VERIF.i® Program
Bureau

Bureau Veritas Agrees to Sell Oil, Petrochemicals, and Coal Testing & Inspection Business Under LEAP | 28 Portfolio Rotation Strategy

In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces…

Read MoreBureau Veritas Agrees to Sell Oil, Petrochemicals, and Coal Testing & Inspection Business Under LEAP | 28 Portfolio Rotation Strategy
Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets

Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets Merck, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive…

Read MoreMerck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets
Verici

Verici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test

Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test Verici Dx plc  a developer of advanced clinical diagnostics for organ transplant, announced it has received clinical laboratory accreditation from the New York State…

Read MoreVerici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test